Immunogenicity of Adjuvanted or Non-adjuvanted H5N1 Booster Vaccine in Adults Primed to A/VN/1194/04

Influenza Clinical Trial

Official title:

A Randomized, Partially Observer-blind, Single-centre Study to Evaluate Safety and Immunogenicity of MF59-adjuvanted or Non-adjuvanted H5N1 Influenza Vaccines in Adults Primed With Adjuvanted Influenza A/Vietnam/1194/04 (H5N1) Vaccine

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00814385
• Other study ID #: UHL10492
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: December 23, 2008
• Last updated: June 2, 2014
• Start date: November 2008
• Est. completion date: December 2013

Study information

• Verified date: June 2014
• Source: University Hospitals, Leicester
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
• Study type: Interventional

Clinical Trial Summary

This study focuses on pre-pandemic priming of man against H5 influenza with the goal of mounting a robust antibody response to small quantities of vaccine either before or during an H5 pandemic.

Description:

OBJECTIVES:

Immunogenicity objectives

1. To evaluate the magnitude of the antibody responses to one or two 'priming' 0.5mL intramuscular (IM) doses of an MF59-adjuvanted A/Vietnam/1194/2004 (H5N1 Clade 1) influenza vaccine, each dose containing 7.5μg of H5N1 haemagglutinin, in immunologically naïve subjects;

2. To examine the kinetics of the antibody responses to one 0.5mL 'booster' intramuscular dose of antigenically drifted MF59-adjuvanted vaccine, or non-adjuvanted antigenically drifted vaccine, given at doses of 3.75 or 7.5μg, in subjects primed with one or two doses of an MF59-adjuvanted A/Vietnam/1194/2004 (H5N1 Clade 1) influenza vaccine;

3. To evaluate the magnitude of the antibody responses to one 0.5mL 'booster' intramuscular dose of antigenically drifted MF59-adjuvanted vaccine, or non-adjuvanted antigenically drifted vaccine, given at doses of 3.75μg or 7.5μg, in subjects primed with one or two doses of an MF59-adjuvanted A/Vietnam/1194/2004 (H5N1 Clade 1) influenza vaccine;

4. To evaluate the breadth of the antibody responses induced by 'priming' (see 1., above), and 'booster' vaccination regimens (see 2., and 3., above), with respect to a representative range of antigenically distinct H5N1 viruses (wild-type and attenuated); and

5. To evaluate the persistence of the antibody responses induced by 'priming' (see 1., above), and 'booster' vaccination regimens (see 2., and 3., above).

Safety objective

1. To evaluate the safety of the administration of one or two 'priming' 0.5mL intramuscular (IM) doses of an MF59-adjuvanted A/Vietnam/1194/2004 (H5N1 Clade 1) influenza vaccine (each dose containing 7.5μg of H5N1 haemagglutinin), in immunologically naïve subjects, followed by one 3.75μg or 7.5μg 'booster' dose of antigenically drifted MF59-adjuvanted H5N1 vaccine, or non-adjuvanted antigenically drifted H5N1 vaccine.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 606
• Est. completion date: December 2013
• Est. primary completion date: September 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Subjects 18 to 59 years of age, or 60 years of age and older, mentally competent, who have signed an informed consent form after having received a detailed explanation of the study protocol;

2. Are in good health or have one or more stable (See footnote) medical conditions, as determined by:

1. Medical history,

2. Physical examination,

3. Clinical judgment of the medical investigator;

3. Are able to understand and comply with all study procedures and to complete study diaries, can be contacted, and will be available for study visits.

4. Subjects who experienced fever (defined as axillary temperature >38oC) within 3 days prior to Visit 1;

5. Subjects who are pregnant or breastfeeding;

6. Females of childbearing potential who refuse to use an acceptable method of birth control for a period of 56 days before and after each vaccination. Adequate contraception is defined as hormonal (e.g., oral, injection, transdermal patch, implant, cervical ring), barrier (e.g., condom with spermicide or diaphragm with spermicide), intrauterine device (e.g., IUD), monogamous relationship with vasectomised partner who has been vasectomised for 6 months or more prior to the subject's study entry, or abstain from heterosexual intercourse (e.g., through sexual orientation or religious or other beliefs about premarital intercourse);

7. Subjects with any serious disease, including:

1. cancer,

2. acute or progressive hepatic disease,

3. acute or progressive renal disease,

4. chronic pulmonary disease requiring home oxygen therapy,

5. active neurological disorder,

6. autoimmune disease (including rheumatoid arthritis);

8. Subjects for whom surgery is planned during the study period;

9. Subjects with a bleeding diathesis;

10. Subjects with hypersensitivity to eggs, chicken protein, chicken feathers, influenza viral protein, neomycin or kanamycin, or any other component of the study vaccine;

11. Subjects with a history of any neurological symptoms and signs, or anaphylactic shock following administration of any vaccine;

12. Subjects with known or suspected impairment/alteration of immune function, for example, resulting from:

1. receipt of oral immunosuppressive therapy (e.g., corticosteroid therapy or cancer chemotherapy) (long-term, inhaled steroids for asthma management is acceptable),

2. receipt of immunostimulants or interferon,

3. receipt of parenteral immunoglobulin preparation, blood products, and/or plasma derivatives within 3 months prior to Visits 1 (Day 1), 2 (Day 22), or 5 (Day 382), or planned during the full length of the study,

4. high risk from developing an immunocompromising disease;

13. Actual or planned receipt of another vaccine during the period 3 weeks before to 3 weeks after vaccination on Days 1, 22, and 382;

14. Subjects with a history of (or current) drug or alcohol abuse (20g/day for females; 30g/day for males) that in the investigator's opinion would interfere with safety of the subject or the evaluation of the study objectives;

15. Subjects who are unable to lead an independent life either physically or mentally;

16. Have participated in a previous study of H5 avian influenza vaccine;

17. Have been previously vaccinated with a vaccine containing MF59 or similar adjuvant;

18. Subjects with any condition, which, in the opinion of the Investigator, might interfere with the evaluation of the study objectives.

Exclusion Criteria:

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Investigator, Outcomes Assessor)

Related Conditions & MeSH terms

• Influenza

Intervention

Biological:
• Aflunov (Single prime, single boost)
Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
• Aflunov (Single prime, single boost)
Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
• Aflunov (single prime, single boost)
Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
• Aflunov (single prime, single boost)
Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
• Aflunov (Double prime, single boost)
Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
• Aflunov (double prime, single boost)
Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
• Aflunov (double prime, single boost)
Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
• Aflunov (double prime, single boost)
Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
• Aflunov (No prime, single boost)
No Priming then MF59-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks

Locations

Country	Name	City	State
United Kingdom	Clincal Trials Unit Leicester Royal Infirmary	Leicester
United Kingdom	University Hospitals Leicester	Leicester	Leicestershire

Sponsors (5)

Lead Sponsor	Collaborator
University Hospitals, Leicester	Medical Research Council, National Institute of Biological Standards and Control, Novartis, Public Health England

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Geometric mean antibody titres to influenza H5N1 by neutralising antibody, HI and SRH		pre vaccination, 3 weeks, 6 weeks, 52 weeks, 55 weeks, 56 weeks	No
Secondary	local and systemic reactogenicity		within 7 days of each vaccination	Yes
Secondary	Seroprotective and seroconversion responses to H5N1 by neutralising antibody, HI and SRH		Prevaccination, 3 weeks, 6 weeks, 52 weeks, 55 weeks and 56 weeks	No